AT

ATUM CO., LTD.

An integrated biologics development partner offering services from DNA sequence to cell bank.

355690 | KO

Overview

Corporate Details

ISIN(s):
KR7355690009
LEI:
Country:
South Korea
Address:
서울특별시 구로구 디지털로31길 38-9 에이스테크노타워1차 6층 603-2호, 구로구

Description

ATUM is an integrated biologics development partner offering a comprehensive suite of services, from virtual DNA sequence to research cell bank. The company's core activities include gene design and synthesis, protein expression and analytics, cell line development, and antibody and protein engineering. Utilizing expertise in machine learning and proprietary platforms like DNA2GO for gene fragments and the lightningHEK and discoCHO expression systems, ATUM facilitates the discovery and optimization processes for its clients. The company operates as a collaborative, one-stop partner for biological engineering projects, providing fully in-house services.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-31 00:00
유상증자결정(종속회사의주요경영사항)
Korean HTML 24.8 KB
2025-12-31 00:00
타법인주식및출자증권취득결정
Korean HTML 26.3 KB
2025-12-23 00:00
[정정제출요구]증권신고서(지분증권)
Korean HTML 2.7 MB
2025-12-23 00:00
주요사항보고서(유상증자결정)
Korean HTML 32.9 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean HTML 1.6 MB
2025-07-29 00:00
타인에대한채무보증결정
Korean HTML 10.4 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean HTML 1.8 MB
2025-05-07 00:00
합병등종료보고서(자산양수도)
Korean HTML 15.1 KB
2025-05-02 00:00
단기차입금증가결정
Korean HTML 9.4 KB
2025-04-29 00:00
주요사항보고서(전환사채권발행결정)
Korean HTML 65.7 KB
2025-04-29 00:00
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean HTML 57.6 KB
2025-04-29 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean HTML 70.0 KB
2025-04-29 00:00
증권발행결과(자율공시) (제4회차 CB)
Korean HTML 6.0 KB
2025-04-02 00:00
합병등종료보고서(자산양수도)
Korean HTML 14.9 KB
2025-04-01 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 24.4 KB

Automate Your Workflow. Get a real-time feed of all ATUM CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ATUM CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ATUM CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.